Tokyo, Sept. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062737) titled 'Efficacy and safety of 0.5% epinastine ophthalmic solution cream in patients of allergic conjunctivitis' on Sept. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Tsurumi University
Condition:
Condition - Patients with allergic conjunctivitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Efficacy of 0.5% epinastine ophthalmic solution cream
Basic objectives2 - Safety
Eligibility:
Age-lower limit - 1
years-old
=
Gender - Male and Female
Key inclusion criteria - Patients who received a full explanation on the objects and methods of this study, expected effects and adverse drug reactions, respect for the compensation, and who themselves of their legal representative voluntarily proved consent for study participation.
Key exclusion criteria - Patients whom the research doctor judged to be unsuitable for this study.
Target Size - 200
Recruitment Status:
Recruitment status - Main results already published
Date of protocol fixation - 2026 Year 05 Month 13 Day
Date of IRB - 2026 Year 05 Month 13 Day
Anticipated trial start date - 2026 Year 05 Month 13 Day
Last follow-up date - 2026 Year 12 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070687
Disclaimer: Curated by HT Syndication.
